What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies to transform human health and sustainability? Company Summary: FL86, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need. FL86 was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA) Generate Biomedicines, Sana Biotechnology (SANA), Tessera Therapeutics, Evelo Biosciences (EVLO), Indigo Agriculture, Seres Therapeutics (MCRB), Syros Pharmaceuticals (SYRS), and Rubius Therapeutics (RUBY).

What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform health care and sustainability? Montai Health is a privately held, early-stage biotechnology company developing a platform for understanding and leveraging complex molecular interactions within organisms to solve global challenges in human health and sustainability. We are looking for an Infrastructure Engineer to join our small and growing team of machine learning scientists & engineers. Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value.

What if…you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform health care and sustainability? Radial Therapeutics, Inc. is a privately held, well-funded, early-stage biotechnology company leveraging novel insights in RNA biology. Radial Therapeutics's proprietary platform identifies novel disease targets and develops new therapeutic modalities targeting RNA, providing new strategies to treat or cure a range of diseases including rare genetic diseases, neurological diseases, and cancers. Radial Therapeutics, Inc. was founded in Flagship's venture creation engine, where companies such as Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), and Editas Medicines (NASDAQ: EDIT) were conceived and created. Since Flagship's founding in 2000, the firm has originated and fostered the development of more than 100 scientific ventures, resulting in over $34 billion in aggregate value, 500 issued patents, and more than 50 clinical trials for novel therapeutic agents.

Artificial intelligence (AI)-enabled data collection and management can be a game changer for life sciences companies in the drug development process. Once the stuff of science fiction, AI has made the leap to practical reality. Yet, to date, most life sciences companies have only scratched the surface of AI's potential. One area that holds particular promise: digital data flow automation for clinical trials. With the power of AI, companies can rapidly digitize clinical-trial processes so they can complete studies faster.

The need for the adoption of AI/ML in Life science companies has increased as the Industry evolves and moves towards high tech cures and precision medicine that is based on specific substances and production methods. The entire value chain is broken down and executed by specialist providers. The Pharma company creates the formula,production is done by specialized contract manufacturers, packaged by specialized companies, medical distributors storing the drugs at specialized conditions before reaching the pharmacies and patients. Managing this complex process for thousands of therapies makes it imperative for Lifesciences companies to start their AI/ML journey at the earliest. There are varied use cases being adopted by companies across the value streams starting from Drug discovery, Clinical trials, Manufacturing, Supply chain, Commercial to Post market surveillance.

Deloitte today announced the launch of its ConvergeHEALTH CognitiveSpark for Marketing artificial intelligence (AI) precision engagement solution, a module of the CognitiveSpark suite. CognitiveSpark for Marketing harnesses the power of AI to boost digital marketing return on investment (ROI) for life sciences companies, helping marketers make AI-powered decisions at scale and with speed. CognitiveSpark for Marketing harnesses the power of AI to boost digital marketing ROI for life sciences companies. A recent Deloitte survey of biopharma executives found that digital innovation is now a burning priority, with 77% of those surveyed saying their organization considers "digital innovation as a competitive differentiator." And in the same survey, 86% of commercial leaders pointed to "health care provider (HCP)/patient engagement as the top use case likely to be impacted by digital innovation."

DENVER, June 16, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the launch of its in-silico drug discovery program in conjunction with researchers at the University of Alberta. Led by top computer-aided drug development expert, Dr. Khaled Barakat, the program is focused on developing artificial intelligence/machine learning (AI/ML) supported drug screenings, including both the ability to build drugs from the receptor up and assess drugs around the receptors of Mydecine's choosing. With its broader R&D capacity in drug development up and running, the in-silico program will enable the Company to more rapidly screen hundreds of thousands of new molecules without the need to produce them, allowing Mydecine to focus on the strongest potential therapeutics for its chemical and natural development programs. Mydecine will also be able to more efficiently screen its proprietary library of novel compounds designed by Chief Science Officer Rob Roscow and Advisory Board member, Dr. Denton Hoyer. "Years of research have shown that the chemical components of psychoactive and non-psychoactive mushrooms can be extremely powerful in a therapeutic setting and yet, there is still so much that we don't understand about how these molecules can affect biological systems. As the next evolution of drug discovery progresses forward, we strongly believe that this new age will be fully led by artificial intelligence and machine learning," said Josh Bartch, CEO of Mydecine.

Leading Fortune 1000 companies have been organizing and analyzing their data to gain business insights for years. Traditional industries with a long history of capturing and managing their data, notably financial services, have decades of experience mining data to better service and grow their customer relationships and manage risk. During the past decade, as data volumes grew, and as new sources of data emerged, Big Data initiatives captured C-suite attention. Today, Fortune 1000 companies are managing exponentially greater volumes and sources of data, while leveraging emerging technology capabilities including machine learning and AI to gain ever more granular insights into market opportunities. Companies are leveraging computers to do the work that they once relied on humans to perform.

We invest in early-stage life sciences companies often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at info@axialvc.com Artificial intelligence (AI) has the potential to transform many parts of life sciences from preclinical drug development and healthcare to synthetic biology and diagnostics. Basic research in AI has made major strides over the last 5 years, and when combined with biologists working with data as much as they work on the bench, the technology is changing how biology is studied and engineered. As a result, AI-first companies in life sciences at first may not look like traditional companies. Whereas, traditional life sciences companies usually have a core set of IP or are based on a biological hypothesis, AI life sciences companies often look like R&D shops or services companies at first.

COVID-19 ushered in major shifts in the way that healthcare professionals (HCPs) interact with life sciences companies, but how have emerging biopharma companies adapted to this new reality? The core challenges small- to mid-sized (SMB) companies face -- limited resources and overburdened staff tasked with a wide span of responsibilities -- have not changed. Yet suddenly, there is growing demand for advanced technology solutions that empower leaner commercial teams to reach more HCPs efficiently. The life sciences industry has been trying to find the right ratio of sales reps to HCPs for decades. Today, there are about 60,000 pharmaceutical sales reps in the U.S., down from 100,000 in the mid-2000s.